Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,7495071,CL/F,The apparent total body clearance of enoxaparin doses (CL/F = 16.7 +/- 5.5 and 13.8 +/- 3.2 ml/min) is significantly smaller than those of nadroparin (CL/F = 21.4 +/- 7.0 ml/min; p < 0.01) and dalteparin (CL/F = 33.3 +/- 11.8 ml/min; p < 0.001) while dalteparin apparent clearance is about 1.5-fold greater (p < 0.001) than that of nadroparin.,"Comparison of the pharmacokinetic profiles of three low molecular mass heparins--dalteparin, enoxaparin and nadroparin--administered subcutaneously in healthy volunteers (doses for prevention of thromboembolism). ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7495071/),[ml] / [min],16.7,3377,DB06779,Dalteparin
,7495071,CL/F,The apparent total body clearance of enoxaparin doses (CL/F = 16.7 +/- 5.5 and 13.8 +/- 3.2 ml/min) is significantly smaller than those of nadroparin (CL/F = 21.4 +/- 7.0 ml/min; p < 0.01) and dalteparin (CL/F = 33.3 +/- 11.8 ml/min; p < 0.001) while dalteparin apparent clearance is about 1.5-fold greater (p < 0.001) than that of nadroparin.,"Comparison of the pharmacokinetic profiles of three low molecular mass heparins--dalteparin, enoxaparin and nadroparin--administered subcutaneously in healthy volunteers (doses for prevention of thromboembolism). ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7495071/),[ml] / [min],13.8,3378,DB06779,Dalteparin
,7495071,CL/F,The apparent total body clearance of enoxaparin doses (CL/F = 16.7 +/- 5.5 and 13.8 +/- 3.2 ml/min) is significantly smaller than those of nadroparin (CL/F = 21.4 +/- 7.0 ml/min; p < 0.01) and dalteparin (CL/F = 33.3 +/- 11.8 ml/min; p < 0.001) while dalteparin apparent clearance is about 1.5-fold greater (p < 0.001) than that of nadroparin.,"Comparison of the pharmacokinetic profiles of three low molecular mass heparins--dalteparin, enoxaparin and nadroparin--administered subcutaneously in healthy volunteers (doses for prevention of thromboembolism). ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7495071/),[ml] / [min],21.4,3379,DB06779,Dalteparin
,7495071,CL/F,The apparent total body clearance of enoxaparin doses (CL/F = 16.7 +/- 5.5 and 13.8 +/- 3.2 ml/min) is significantly smaller than those of nadroparin (CL/F = 21.4 +/- 7.0 ml/min; p < 0.01) and dalteparin (CL/F = 33.3 +/- 11.8 ml/min; p < 0.001) while dalteparin apparent clearance is about 1.5-fold greater (p < 0.001) than that of nadroparin.,"Comparison of the pharmacokinetic profiles of three low molecular mass heparins--dalteparin, enoxaparin and nadroparin--administered subcutaneously in healthy volunteers (doses for prevention of thromboembolism). ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7495071/),[ml] / [min],33.3,3380,DB06779,Dalteparin
,7495071,apparent elimination half life t1/2,These differences in the disposition profiles explain why the apparent elimination half life t1/2 values of the LMMHs compared here are different: dalteparin: 2.8 h; nadroparin: 3.7 h; and enoxaparin: 4.1 h.,"Comparison of the pharmacokinetic profiles of three low molecular mass heparins--dalteparin, enoxaparin and nadroparin--administered subcutaneously in healthy volunteers (doses for prevention of thromboembolism). ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7495071/),h,2.8,3381,DB06779,Dalteparin
,7495071,apparent elimination half life t1/2,These differences in the disposition profiles explain why the apparent elimination half life t1/2 values of the LMMHs compared here are different: dalteparin: 2.8 h; nadroparin: 3.7 h; and enoxaparin: 4.1 h.,"Comparison of the pharmacokinetic profiles of three low molecular mass heparins--dalteparin, enoxaparin and nadroparin--administered subcutaneously in healthy volunteers (doses for prevention of thromboembolism). ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7495071/),h,3.7,3382,DB06779,Dalteparin
,7495071,apparent elimination half life t1/2,These differences in the disposition profiles explain why the apparent elimination half life t1/2 values of the LMMHs compared here are different: dalteparin: 2.8 h; nadroparin: 3.7 h; and enoxaparin: 4.1 h.,"Comparison of the pharmacokinetic profiles of three low molecular mass heparins--dalteparin, enoxaparin and nadroparin--administered subcutaneously in healthy volunteers (doses for prevention of thromboembolism). ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7495071/),h,4.1,3383,DB06779,Dalteparin
,28375032,T1/2,"The T1/2 of reference and test were 2.88 ± 1.21 h and 2.76 ± 0.97 h for Anti-Xa, 1.87 ± 0.62 h and 1.96 ± 1.52 h for Anti-IIa.",Pharmacodynamic properties and bioequivalence of dalteparin sodium subcutaneous injection in healthy Chinese male subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28375032/),h,2.88,4723,DB06779,Dalteparin
,28375032,T1/2,"The T1/2 of reference and test were 2.88 ± 1.21 h and 2.76 ± 0.97 h for Anti-Xa, 1.87 ± 0.62 h and 1.96 ± 1.52 h for Anti-IIa.",Pharmacodynamic properties and bioequivalence of dalteparin sodium subcutaneous injection in healthy Chinese male subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28375032/),h,2.76,4724,DB06779,Dalteparin
,28375032,T1/2,"The T1/2 of reference and test were 2.88 ± 1.21 h and 2.76 ± 0.97 h for Anti-Xa, 1.87 ± 0.62 h and 1.96 ± 1.52 h for Anti-IIa.",Pharmacodynamic properties and bioequivalence of dalteparin sodium subcutaneous injection in healthy Chinese male subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28375032/),h,1.87,4725,DB06779,Dalteparin
,28375032,T1/2,"The T1/2 of reference and test were 2.88 ± 1.21 h and 2.76 ± 0.97 h for Anti-Xa, 1.87 ± 0.62 h and 1.96 ± 1.52 h for Anti-IIa.",Pharmacodynamic properties and bioequivalence of dalteparin sodium subcutaneous injection in healthy Chinese male subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28375032/),h,1.96,4726,DB06779,Dalteparin
,9748709,elimination of half-life,The elimination of half-life of DAS was 9.90 h and was 6.0 times longer than that of DLS and 16.5 times longer than that of heparin.,"Pharmacokinetics of danaparoid sodium, dalteparin sodium and heparin determined by inhibitory effect on the activated coagulation factor X activity after single intravenous administration in rabbits. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9748709/),h,9.90,10669,DB06779,Dalteparin
,9748709,area under the plasma concentration-time curve (AUC),The area under the plasma concentration-time curve (AUC) of DAS was 47.13 +/- 14.55 anti-Xa U.h/ml and was 2.4 times larger than that of DLS and 2.9 times larger than that of heparin.,"Pharmacokinetics of danaparoid sodium, dalteparin sodium and heparin determined by inhibitory effect on the activated coagulation factor X activity after single intravenous administration in rabbits. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9748709/),[h·u] / [ml],47.13,10670,DB06779,Dalteparin
,9748709,urinary cumulative excretion,"The urinary cumulative excretion of anti-Xa activity of DAS and DLS was 42.6 +/- 6.4% and 16.4 +/- 0.8% of dose, respectively, in 24 h after dosing, respectively.","Pharmacokinetics of danaparoid sodium, dalteparin sodium and heparin determined by inhibitory effect on the activated coagulation factor X activity after single intravenous administration in rabbits. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9748709/),%,42.6,10671,DB06779,Dalteparin
,9748709,urinary cumulative excretion,"The urinary cumulative excretion of anti-Xa activity of DAS and DLS was 42.6 +/- 6.4% and 16.4 +/- 0.8% of dose, respectively, in 24 h after dosing, respectively.","Pharmacokinetics of danaparoid sodium, dalteparin sodium and heparin determined by inhibitory effect on the activated coagulation factor X activity after single intravenous administration in rabbits. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9748709/),%,16.4,10672,DB06779,Dalteparin
,11251329,plasma anti-factor Xa levels,"The plasma anti-factor Xa levels in the 6 healthy volunteers who received a microenema containing 25,000 U of LMWH with 20 mg/ml of Sch were 0.38 U/ml at 15 min and 0.1 U/ml at 240 min.",Intestinal absorption of low molecular weight heparin in animals and human subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11251329/),[u] / [ml],0.38,14587,DB06779,Dalteparin
,11251329,plasma anti-factor Xa levels,"The plasma anti-factor Xa levels in the 6 healthy volunteers who received a microenema containing 25,000 U of LMWH with 20 mg/ml of Sch were 0.38 U/ml at 15 min and 0.1 U/ml at 240 min.",Intestinal absorption of low molecular weight heparin in animals and human subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11251329/),[u] / [ml],0.1,14588,DB06779,Dalteparin
,32827160,CL/F,"The estimates of CL/F and Vd/F in the full model were 929 mL/h and 7180 mL, respectively, for a reference female patient aged 12 years with body weight of 43 kg.",Population Pharmacokinetic Analysis of Dalteparin in Pediatric Patients With Venous Thromboembolism. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32827160/),[ml] / [h],929,15430,DB06779,Dalteparin
,32827160,Vd/F,"The estimates of CL/F and Vd/F in the full model were 929 mL/h and 7180 mL, respectively, for a reference female patient aged 12 years with body weight of 43 kg.",Population Pharmacokinetic Analysis of Dalteparin in Pediatric Patients With Venous Thromboembolism. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32827160/),ml,7180,15431,DB06779,Dalteparin
>,19175499,bioaccumulation,No bioaccumulation>30% could be found up to day 10 even in patients with severe RI.,Study of bioaccumulation of dalteparin at a prophylactic dose in patients with various degrees of impaired renal function. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19175499/),%,30,19178,DB06779,Dalteparin
>,19175499,bioaccumulation,"The use of dalteparin at a prophylactic dose was not associated with a bioaccumulation>30% even in patients with severe renal insufficiency during a median follow-up of 10 days (IQR 4-13, range 1-20).",Study of bioaccumulation of dalteparin at a prophylactic dose in patients with various degrees of impaired renal function. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19175499/),%,30,19179,DB06779,Dalteparin
,11228340,Oral bioavailability,"Oral bioavailability, measured as melagatran in plasma, is about 20% after oral administration of H 376/95, which is 2.7-5.5 times higher than after oral administration of melagatran.","The direct thrombin inhibitor melagatran and its oral prodrug H 376/95: intestinal absorption properties, biochemical and pharmacodynamic effects. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11228340/),%,20,24799,DB06779,Dalteparin
,11228340,inhibition constant (K(i)) ratio,"Pharmacodynamic properties: H 376/95 is inactive towards human alpha-thrombin compared with melagatran [inhibition constant (K(i)) ratio, 185 times], a potential advantage for patients with silent gastrointestinal bleeding.","The direct thrombin inhibitor melagatran and its oral prodrug H 376/95: intestinal absorption properties, biochemical and pharmacodynamic effects. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11228340/),times,185,24800,DB06779,Dalteparin
,27536434,A max,"For anti-Xa activity, the means (SD) of A max (IU/mL) were 1.34 (0.25) [range = 0.59-2.03] and 1.39 (0.35) [range = 0.65-2.69]; AUC0- t (IU•h/mL) values were 11.4 (2.76) [range = 2.89-19.5] and 12.1 (2.87) [range = 2.52-21.30]; AUC0 - ∞ (IU•h/mL) values were 13.1 (3.59) [range = 3.15-28.2] and 14.5 (4.97) [range = 2.79-36.1] for test and branded formulations, respectively.","Bioequivalence study of two subcutaneous formulations of dalteparin: randomized, single-dose, two-sequence, two-period, cross-over study in healthy volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27536434/),[iu] / [ml],1.34,38605,DB06779,Dalteparin
,27536434,A max,"For anti-Xa activity, the means (SD) of A max (IU/mL) were 1.34 (0.25) [range = 0.59-2.03] and 1.39 (0.35) [range = 0.65-2.69]; AUC0- t (IU•h/mL) values were 11.4 (2.76) [range = 2.89-19.5] and 12.1 (2.87) [range = 2.52-21.30]; AUC0 - ∞ (IU•h/mL) values were 13.1 (3.59) [range = 3.15-28.2] and 14.5 (4.97) [range = 2.79-36.1] for test and branded formulations, respectively.","Bioequivalence study of two subcutaneous formulations of dalteparin: randomized, single-dose, two-sequence, two-period, cross-over study in healthy volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27536434/),[iu] / [ml],1.39,38606,DB06779,Dalteparin
,27536434,AUC0- t,"For anti-Xa activity, the means (SD) of A max (IU/mL) were 1.34 (0.25) [range = 0.59-2.03] and 1.39 (0.35) [range = 0.65-2.69]; AUC0- t (IU•h/mL) values were 11.4 (2.76) [range = 2.89-19.5] and 12.1 (2.87) [range = 2.52-21.30]; AUC0 - ∞ (IU•h/mL) values were 13.1 (3.59) [range = 3.15-28.2] and 14.5 (4.97) [range = 2.79-36.1] for test and branded formulations, respectively.","Bioequivalence study of two subcutaneous formulations of dalteparin: randomized, single-dose, two-sequence, two-period, cross-over study in healthy volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27536434/),[h·iu] / [ml],11.4,38607,DB06779,Dalteparin
,27536434,AUC0- t,"For anti-Xa activity, the means (SD) of A max (IU/mL) were 1.34 (0.25) [range = 0.59-2.03] and 1.39 (0.35) [range = 0.65-2.69]; AUC0- t (IU•h/mL) values were 11.4 (2.76) [range = 2.89-19.5] and 12.1 (2.87) [range = 2.52-21.30]; AUC0 - ∞ (IU•h/mL) values were 13.1 (3.59) [range = 3.15-28.2] and 14.5 (4.97) [range = 2.79-36.1] for test and branded formulations, respectively.","Bioequivalence study of two subcutaneous formulations of dalteparin: randomized, single-dose, two-sequence, two-period, cross-over study in healthy volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27536434/),[h·iu] / [ml],12.1,38608,DB06779,Dalteparin
,27536434,AUC0 - ∞,"For anti-Xa activity, the means (SD) of A max (IU/mL) were 1.34 (0.25) [range = 0.59-2.03] and 1.39 (0.35) [range = 0.65-2.69]; AUC0- t (IU•h/mL) values were 11.4 (2.76) [range = 2.89-19.5] and 12.1 (2.87) [range = 2.52-21.30]; AUC0 - ∞ (IU•h/mL) values were 13.1 (3.59) [range = 3.15-28.2] and 14.5 (4.97) [range = 2.79-36.1] for test and branded formulations, respectively.","Bioequivalence study of two subcutaneous formulations of dalteparin: randomized, single-dose, two-sequence, two-period, cross-over study in healthy volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27536434/),[h·iu] / [ml],13.1,38609,DB06779,Dalteparin
,27536434,AUC0 - ∞,"For anti-Xa activity, the means (SD) of A max (IU/mL) were 1.34 (0.25) [range = 0.59-2.03] and 1.39 (0.35) [range = 0.65-2.69]; AUC0- t (IU•h/mL) values were 11.4 (2.76) [range = 2.89-19.5] and 12.1 (2.87) [range = 2.52-21.30]; AUC0 - ∞ (IU•h/mL) values were 13.1 (3.59) [range = 3.15-28.2] and 14.5 (4.97) [range = 2.79-36.1] for test and branded formulations, respectively.","Bioequivalence study of two subcutaneous formulations of dalteparin: randomized, single-dose, two-sequence, two-period, cross-over study in healthy volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27536434/),[h·iu] / [ml],14.5,38610,DB06779,Dalteparin
,27536434,A max,"For anti-IIa activity, the means (SD) of A max (IU/mL) were 0.34 (0.12) [range = 0.14-0.72] and 0.34 (0.13) [range = 0.11-0.84]; AUC0- t (IU•h/mL) values were 2.05 (0.72) [range = 0.61-4.69] and 2.11 (0.76) [range = 0.84-4.80]; AUC0 - ∞ (IU•h/mL) values were 2.47 (0.80) [range = 0.76-6.29] and 2.61 (0.86) [range = 1.31-5.36], for test and branded formulations, respectively.","Bioequivalence study of two subcutaneous formulations of dalteparin: randomized, single-dose, two-sequence, two-period, cross-over study in healthy volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27536434/),[iu] / [ml],0.34,38611,DB06779,Dalteparin
,27536434,A max,"For anti-IIa activity, the means (SD) of A max (IU/mL) were 0.34 (0.12) [range = 0.14-0.72] and 0.34 (0.13) [range = 0.11-0.84]; AUC0- t (IU•h/mL) values were 2.05 (0.72) [range = 0.61-4.69] and 2.11 (0.76) [range = 0.84-4.80]; AUC0 - ∞ (IU•h/mL) values were 2.47 (0.80) [range = 0.76-6.29] and 2.61 (0.86) [range = 1.31-5.36], for test and branded formulations, respectively.","Bioequivalence study of two subcutaneous formulations of dalteparin: randomized, single-dose, two-sequence, two-period, cross-over study in healthy volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27536434/),[iu] / [ml],0.34,38612,DB06779,Dalteparin
,27536434,AUC0- t,"For anti-IIa activity, the means (SD) of A max (IU/mL) were 0.34 (0.12) [range = 0.14-0.72] and 0.34 (0.13) [range = 0.11-0.84]; AUC0- t (IU•h/mL) values were 2.05 (0.72) [range = 0.61-4.69] and 2.11 (0.76) [range = 0.84-4.80]; AUC0 - ∞ (IU•h/mL) values were 2.47 (0.80) [range = 0.76-6.29] and 2.61 (0.86) [range = 1.31-5.36], for test and branded formulations, respectively.","Bioequivalence study of two subcutaneous formulations of dalteparin: randomized, single-dose, two-sequence, two-period, cross-over study in healthy volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27536434/),[h·iu] / [ml],2.05,38613,DB06779,Dalteparin
,27536434,AUC0- t,"For anti-IIa activity, the means (SD) of A max (IU/mL) were 0.34 (0.12) [range = 0.14-0.72] and 0.34 (0.13) [range = 0.11-0.84]; AUC0- t (IU•h/mL) values were 2.05 (0.72) [range = 0.61-4.69] and 2.11 (0.76) [range = 0.84-4.80]; AUC0 - ∞ (IU•h/mL) values were 2.47 (0.80) [range = 0.76-6.29] and 2.61 (0.86) [range = 1.31-5.36], for test and branded formulations, respectively.","Bioequivalence study of two subcutaneous formulations of dalteparin: randomized, single-dose, two-sequence, two-period, cross-over study in healthy volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27536434/),[h·iu] / [ml],2.11,38614,DB06779,Dalteparin
,27536434,AUC0 - ∞,"For anti-IIa activity, the means (SD) of A max (IU/mL) were 0.34 (0.12) [range = 0.14-0.72] and 0.34 (0.13) [range = 0.11-0.84]; AUC0- t (IU•h/mL) values were 2.05 (0.72) [range = 0.61-4.69] and 2.11 (0.76) [range = 0.84-4.80]; AUC0 - ∞ (IU•h/mL) values were 2.47 (0.80) [range = 0.76-6.29] and 2.61 (0.86) [range = 1.31-5.36], for test and branded formulations, respectively.","Bioequivalence study of two subcutaneous formulations of dalteparin: randomized, single-dose, two-sequence, two-period, cross-over study in healthy volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27536434/),[h·iu] / [ml],2.47,38615,DB06779,Dalteparin
,27536434,AUC0 - ∞,"For anti-IIa activity, the means (SD) of A max (IU/mL) were 0.34 (0.12) [range = 0.14-0.72] and 0.34 (0.13) [range = 0.11-0.84]; AUC0- t (IU•h/mL) values were 2.05 (0.72) [range = 0.61-4.69] and 2.11 (0.76) [range = 0.84-4.80]; AUC0 - ∞ (IU•h/mL) values were 2.47 (0.80) [range = 0.76-6.29] and 2.61 (0.86) [range = 1.31-5.36], for test and branded formulations, respectively.","Bioequivalence study of two subcutaneous formulations of dalteparin: randomized, single-dose, two-sequence, two-period, cross-over study in healthy volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27536434/),[h·iu] / [ml],2.61,38616,DB06779,Dalteparin
,15527497,TG,"TG increased from 2.14 mmol/L before, to 2.59 mmol/L after the dialysis (p < 0.01).","Lipoprotein lipase in hemodialysis patients: indications that low molecular weight heparin depletes functional stores, despite low plasma levels of the enzyme. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15527497/),[mM] / [l],2.14,39636,DB06779,Dalteparin
,15527497,TG,"TG increased from 2.14 mmol/L before, to 2.59 mmol/L after the dialysis (p < 0.01).","Lipoprotein lipase in hemodialysis patients: indications that low molecular weight heparin depletes functional stores, despite low plasma levels of the enzyme. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15527497/),[mM] / [l],2.59,39637,DB06779,Dalteparin
>,8707165,F,"Since they are mainly administered subcutaneously, then compared to UFH, they are almost completely absorbed (F > or = 90%) and, in contrast to UFH, those for which data are available in the literature exhibit linear pharmacokinetics with proportionality between anti-Xa (and anti-IIa in some cases) plasma concentration and dose, and stationary distribution volume and clearance processes when the dosage is increased.","Low-molecular-weight heparins: an overview of their pharmacodynamics, pharmacokinetics and metabolism in humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8707165/),%,90,39903,DB06779,Dalteparin
,9200334,relative bioavailability,"The relative bioavailability of the aXa activity, aIIa activity, and the plasma concentrations ranged between 70 and 100%.",Comparison of the pharmacodynamic and pharmacokinetic profiles of two low-molecular-mass heparins in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9200334/),%,70 and 100,45896,DB06779,Dalteparin
,17139369,maximum concentration (Cmax ),The mean (range) PK parameters determined after the 4th dose were as follows: i) maximum concentration (Cmax ) was 0.31 IU/ml (0.06 to 0.55 IU/ml); ii) time to Cmax was 3.55 hours (2.59 to 4.96 hr); iii) area under the curve was 3.24 IU*hr/ml (0.64 to 6.44 IU*hr/ml); iv) half-life was 3.82 hr (2.03 to 9.63 hr); and v) trough anti-factor Xa activity 0.04 IU/ml (0.02 to 0.08 IU/ml).,A multi-dose pharmacokinetic study of dalteparin in haemodialysis patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17139369/),[iu] / [ml],0.31,52147,DB06779,Dalteparin
,17139369,time to Cmax,The mean (range) PK parameters determined after the 4th dose were as follows: i) maximum concentration (Cmax ) was 0.31 IU/ml (0.06 to 0.55 IU/ml); ii) time to Cmax was 3.55 hours (2.59 to 4.96 hr); iii) area under the curve was 3.24 IU*hr/ml (0.64 to 6.44 IU*hr/ml); iv) half-life was 3.82 hr (2.03 to 9.63 hr); and v) trough anti-factor Xa activity 0.04 IU/ml (0.02 to 0.08 IU/ml).,A multi-dose pharmacokinetic study of dalteparin in haemodialysis patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17139369/),h,3.55,52148,DB06779,Dalteparin
,17139369,area under the curve,The mean (range) PK parameters determined after the 4th dose were as follows: i) maximum concentration (Cmax ) was 0.31 IU/ml (0.06 to 0.55 IU/ml); ii) time to Cmax was 3.55 hours (2.59 to 4.96 hr); iii) area under the curve was 3.24 IU*hr/ml (0.64 to 6.44 IU*hr/ml); iv) half-life was 3.82 hr (2.03 to 9.63 hr); and v) trough anti-factor Xa activity 0.04 IU/ml (0.02 to 0.08 IU/ml).,A multi-dose pharmacokinetic study of dalteparin in haemodialysis patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17139369/),[h·iu] / [ml],3.24,52149,DB06779,Dalteparin
,17139369,half-life,The mean (range) PK parameters determined after the 4th dose were as follows: i) maximum concentration (Cmax ) was 0.31 IU/ml (0.06 to 0.55 IU/ml); ii) time to Cmax was 3.55 hours (2.59 to 4.96 hr); iii) area under the curve was 3.24 IU*hr/ml (0.64 to 6.44 IU*hr/ml); iv) half-life was 3.82 hr (2.03 to 9.63 hr); and v) trough anti-factor Xa activity 0.04 IU/ml (0.02 to 0.08 IU/ml).,A multi-dose pharmacokinetic study of dalteparin in haemodialysis patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17139369/),h,3.82,52150,DB06779,Dalteparin
,17139369,trough anti-factor Xa activity,The mean (range) PK parameters determined after the 4th dose were as follows: i) maximum concentration (Cmax ) was 0.31 IU/ml (0.06 to 0.55 IU/ml); ii) time to Cmax was 3.55 hours (2.59 to 4.96 hr); iii) area under the curve was 3.24 IU*hr/ml (0.64 to 6.44 IU*hr/ml); iv) half-life was 3.82 hr (2.03 to 9.63 hr); and v) trough anti-factor Xa activity 0.04 IU/ml (0.02 to 0.08 IU/ml).,A multi-dose pharmacokinetic study of dalteparin in haemodialysis patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17139369/),[iu] / [ml],0.04,52151,DB06779,Dalteparin
,27347822,peak anti-Xa activity,"RESULTS 2 hours after the second injection, the target peak anti-Xa activity range of 0.5 to 1.0 U/mL was achieved in all cats, whereas median trough values remained below this range.",Assessment of the effects of dalteparin on coagulation variables and determination of a treatment schedule for use in cats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27347822/),[u] / [ml],0.5 to 1.0,56282,DB06779,Dalteparin
,16790078,Cmax,"The mean Cmax value was not different between ICU patients with and without subcutaneous oedema (0.15 +/- 0.02 versus 0.14 +/- 0.02 IU/ml, p = 0.34).",Anti-Xa activity after subcutaneous administration of dalteparin in ICU patients with and without subcutaneous oedema: a pilot study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16790078/),[iu] / [ml],0.15,67308,DB06779,Dalteparin
,16790078,Cmax,"The mean Cmax value was not different between ICU patients with and without subcutaneous oedema (0.15 +/- 0.02 versus 0.14 +/- 0.02 IU/ml, p = 0.34).",Anti-Xa activity after subcutaneous administration of dalteparin in ICU patients with and without subcutaneous oedema: a pilot study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16790078/),[iu] / [ml],0.14,67309,DB06779,Dalteparin
,16790078,AUC(0-24 h),"In the index group, the mean AUC(0-24 h) value was slightly higher compared with the reference group (1.50 +/- 0.31 versus 1.15 +/- 0.25 h.IU/ml, p = 0.31).",Anti-Xa activity after subcutaneous administration of dalteparin in ICU patients with and without subcutaneous oedema: a pilot study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16790078/),[h·iu] / [ml],1.50,67310,DB06779,Dalteparin
,16790078,AUC(0-24 h),"In the index group, the mean AUC(0-24 h) value was slightly higher compared with the reference group (1.50 +/- 0.31 versus 1.15 +/- 0.25 h.IU/ml, p = 0.31).",Anti-Xa activity after subcutaneous administration of dalteparin in ICU patients with and without subcutaneous oedema: a pilot study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16790078/),[h·iu] / [ml],1.15,67311,DB06779,Dalteparin
,24401673,anti-Xa activity,The mean anti-Xa activity at the end of haemodialysis (Clast) was 0.15 IU/ml in group 1 and 0.60 IU/ml in group 2.,Pharmacokinetics of dalteparin during haemodialysis. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24401673/),[iu] / [ml],0.15,78657,DB06779,Dalteparin
,24401673,anti-Xa activity,The mean anti-Xa activity at the end of haemodialysis (Clast) was 0.15 IU/ml in group 1 and 0.60 IU/ml in group 2.,Pharmacokinetics of dalteparin during haemodialysis. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24401673/),[iu] / [ml],0.60,78658,DB06779,Dalteparin
,12532174,bioavailability,"Phase I trials have shown a 100% bioavailability after subcutaneous (s.c.) administration, a rapid onset of action and an approximate half-life of 13.5 h.",Fondaparinux sodium. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12532174/),%,100,83385,DB06779,Dalteparin
,12532174,half-life,"Phase I trials have shown a 100% bioavailability after subcutaneous (s.c.) administration, a rapid onset of action and an approximate half-life of 13.5 h.",Fondaparinux sodium. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12532174/),h,13.5,83386,DB06779,Dalteparin
,12851531,IC(50),"The ETP IC(50) values for melagatran and the low-molecular-weight heparin dalteparin were 0.44 micromol/l and 0.06 IU/ml, respectively.","Effects of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, and dalteparin on the endogenous thrombin potential in venous blood from healthy male subjects. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12851531/),[μM] / [l],0.44,99817,DB06779,Dalteparin
,12851531,IC(50),"The ETP IC(50) values for melagatran and the low-molecular-weight heparin dalteparin were 0.44 micromol/l and 0.06 IU/ml, respectively.","Effects of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, and dalteparin on the endogenous thrombin potential in venous blood from healthy male subjects. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12851531/),[iu] / [ml],0.06,99818,DB06779,Dalteparin
,9690805,anti-FXa activity,An anti-FXa activity of 0.20-0.40 IU/ml 3 h after injection was obtained.,A pharmacokinetic study of dalteparin (Fragmin) during late pregnancy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9690805/),[iu] / [ml],0.20-0.40,109722,DB06779,Dalteparin
,9690805,Cmax,"The means +/- SD, when comparing morning and evening doses for 5000 IU, were: Cmax 0.21 +/- 0.05 and 0.20 +/- 0.05 IU anti-FXa/ml, AUC 0-24 h 1.97 +/- 0.46 and 1.93 +/- 0.55 IU x h/ml and tmax 3.71 +/- 0.89 and 4.32 +/- 1.60 h, respectively (NS).",A pharmacokinetic study of dalteparin (Fragmin) during late pregnancy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9690805/),[a·anti-f·iu] / [ml],0.21,109723,DB06779,Dalteparin
,9690805,Cmax,"The means +/- SD, when comparing morning and evening doses for 5000 IU, were: Cmax 0.21 +/- 0.05 and 0.20 +/- 0.05 IU anti-FXa/ml, AUC 0-24 h 1.97 +/- 0.46 and 1.93 +/- 0.55 IU x h/ml and tmax 3.71 +/- 0.89 and 4.32 +/- 1.60 h, respectively (NS).",A pharmacokinetic study of dalteparin (Fragmin) during late pregnancy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9690805/),[a·anti-f·iu] / [ml],0.20,109724,DB06779,Dalteparin
,9690805,AUC 0-24 h,"The means +/- SD, when comparing morning and evening doses for 5000 IU, were: Cmax 0.21 +/- 0.05 and 0.20 +/- 0.05 IU anti-FXa/ml, AUC 0-24 h 1.97 +/- 0.46 and 1.93 +/- 0.55 IU x h/ml and tmax 3.71 +/- 0.89 and 4.32 +/- 1.60 h, respectively (NS).",A pharmacokinetic study of dalteparin (Fragmin) during late pregnancy. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9690805/),[h·iu] / [ml],1.97,109725,DB06779,Dalteparin
,9690805,AUC 0-24 h,"The means +/- SD, when comparing morning and evening doses for 5000 IU, were: Cmax 0.21 +/- 0.05 and 0.20 +/- 0.05 IU anti-FXa/ml, AUC 0-24 h 1.97 +/- 0.46 and 1.93 +/- 0.55 IU x h/ml and tmax 3.71 +/- 0.89 and 4.32 +/- 1.60 h, respectively (NS).",A pharmacokinetic study of dalteparin (Fragmin) during late pregnancy. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9690805/),[h·iu] / [ml],1.93,109726,DB06779,Dalteparin
,9690805,tmax,"The means +/- SD, when comparing morning and evening doses for 5000 IU, were: Cmax 0.21 +/- 0.05 and 0.20 +/- 0.05 IU anti-FXa/ml, AUC 0-24 h 1.97 +/- 0.46 and 1.93 +/- 0.55 IU x h/ml and tmax 3.71 +/- 0.89 and 4.32 +/- 1.60 h, respectively (NS).",A pharmacokinetic study of dalteparin (Fragmin) during late pregnancy. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9690805/),h,3.71,109727,DB06779,Dalteparin
,9690805,tmax,"The means +/- SD, when comparing morning and evening doses for 5000 IU, were: Cmax 0.21 +/- 0.05 and 0.20 +/- 0.05 IU anti-FXa/ml, AUC 0-24 h 1.97 +/- 0.46 and 1.93 +/- 0.55 IU x h/ml and tmax 3.71 +/- 0.89 and 4.32 +/- 1.60 h, respectively (NS).",A pharmacokinetic study of dalteparin (Fragmin) during late pregnancy. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9690805/),h,4.32,109728,DB06779,Dalteparin
,9690805,half-lives,"The half-lives after a morning and an evening dose of 5000 IU dalteparin were 4.92 +/- 2.80 and 3.87 +/- 1.15 h, respectively (NS).",A pharmacokinetic study of dalteparin (Fragmin) during late pregnancy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9690805/),h,4.92,109729,DB06779,Dalteparin
,9690805,half-lives,"The half-lives after a morning and an evening dose of 5000 IU dalteparin were 4.92 +/- 2.80 and 3.87 +/- 1.15 h, respectively (NS).",A pharmacokinetic study of dalteparin (Fragmin) during late pregnancy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9690805/),h,3.87,109730,DB06779,Dalteparin
,15928099,clearance,Median iohexol clearance was similar with dalteparin (99-103 ml/min) and melagatran in the dialysis fluid (98-100 ml/min).,Prevention of clot formation during haemodialysis using the direct thrombin inhibitor melagatran in patients with chronic uraemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15928099/),[ml] / [min],99-103,118657,DB06779,Dalteparin
,15928099,clearance,Median iohexol clearance was similar with dalteparin (99-103 ml/min) and melagatran in the dialysis fluid (98-100 ml/min).,Prevention of clot formation during haemodialysis using the direct thrombin inhibitor melagatran in patients with chronic uraemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15928099/),[ml] / [min],98-100,118658,DB06779,Dalteparin
,15928099,clearance,"While the clearance of melagatran was low in patients with renal failure (mean+/-SD, 0.93+/-0.36 l/h), haemodialysis provided efficient clearance of melagatran (7.20+/-0.76 l/h).",Prevention of clot formation during haemodialysis using the direct thrombin inhibitor melagatran in patients with chronic uraemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15928099/),[l] / [h],0.93,118659,DB06779,Dalteparin
,15928099,clearance,"While the clearance of melagatran was low in patients with renal failure (mean+/-SD, 0.93+/-0.36 l/h), haemodialysis provided efficient clearance of melagatran (7.20+/-0.76 l/h).",Prevention of clot formation during haemodialysis using the direct thrombin inhibitor melagatran in patients with chronic uraemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15928099/),[l] / [h],7.20,118660,DB06779,Dalteparin
,15928099,clearance,Melagatran clearance by dialysis (104+/-10 ml/min) was comparable to iohexol clearance.,Prevention of clot formation during haemodialysis using the direct thrombin inhibitor melagatran in patients with chronic uraemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15928099/),[ml] / [min],104,118661,DB06779,Dalteparin
,10763553,peak plasma heparin activity,"After intravenous application of 25, 50 and 100 anti-fXaU./kg body weight (BW) the mean peak plasma heparin activity of 0.52 +/- 0.12 (x +/- s), 1.08 +/- 0.23 and 1.86 +/- 0.17 anti-fXaU./ml, respectively, was measured.",[Phamacokinetics of low-molecular-weight heparins Fragmin D in dogs]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10763553/),[anti-f·au] / [ml],0.52,124001,DB06779,Dalteparin
,10763553,peak plasma heparin activity,"After intravenous application of 25, 50 and 100 anti-fXaU./kg body weight (BW) the mean peak plasma heparin activity of 0.52 +/- 0.12 (x +/- s), 1.08 +/- 0.23 and 1.86 +/- 0.17 anti-fXaU./ml, respectively, was measured.",[Phamacokinetics of low-molecular-weight heparins Fragmin D in dogs]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10763553/),[anti-f·au] / [ml],1.08,124002,DB06779,Dalteparin
,10763553,peak plasma heparin activity,"After intravenous application of 25, 50 and 100 anti-fXaU./kg body weight (BW) the mean peak plasma heparin activity of 0.52 +/- 0.12 (x +/- s), 1.08 +/- 0.23 and 1.86 +/- 0.17 anti-fXaU./ml, respectively, was measured.",[Phamacokinetics of low-molecular-weight heparins Fragmin D in dogs]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10763553/),[anti-f·au] / [ml],1.86,124003,DB06779,Dalteparin
,10763553,maximum heparin activity,"After subcutaneous application of 50, 100 and 200 anti-fXaU./kg BW maximum heparin activity in the plasma was determined after 144-216 minutes (mean values) of 0.28 +/- 0.01, 0.52 +/- 0.06 or 1.09 +/- 0.20 anti-fXaU./ml.",[Phamacokinetics of low-molecular-weight heparins Fragmin D in dogs]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10763553/),[anti-f·au] / [ml],0.28,124004,DB06779,Dalteparin
,10763553,maximum heparin activity,"After subcutaneous application of 50, 100 and 200 anti-fXaU./kg BW maximum heparin activity in the plasma was determined after 144-216 minutes (mean values) of 0.28 +/- 0.01, 0.52 +/- 0.06 or 1.09 +/- 0.20 anti-fXaU./ml.",[Phamacokinetics of low-molecular-weight heparins Fragmin D in dogs]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10763553/),[anti-f·au] / [ml],0.52,124005,DB06779,Dalteparin
,10763553,maximum heparin activity,"After subcutaneous application of 50, 100 and 200 anti-fXaU./kg BW maximum heparin activity in the plasma was determined after 144-216 minutes (mean values) of 0.28 +/- 0.01, 0.52 +/- 0.06 or 1.09 +/- 0.20 anti-fXaU./ml.",[Phamacokinetics of low-molecular-weight heparins Fragmin D in dogs]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10763553/),[anti-f·au] / [ml],1.09,124006,DB06779,Dalteparin
,10763553,plasma terminal half-life (t50),Intravenous application of LMWH has a short plasma terminal half-life (t50) between 49 and 76 minutes which depended on the dosage.,[Phamacokinetics of low-molecular-weight heparins Fragmin D in dogs]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10763553/),min,49 and 76,124007,DB06779,Dalteparin
,10763553,t50,"After injection of 50, 100 and 200 anti-fXaU./kg BW t50 values of 81, 123 and 182 minutes were calculated.",[Phamacokinetics of low-molecular-weight heparins Fragmin D in dogs]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10763553/),min,81,124008,DB06779,Dalteparin
,10763553,t50,"After injection of 50, 100 and 200 anti-fXaU./kg BW t50 values of 81, 123 and 182 minutes were calculated.",[Phamacokinetics of low-molecular-weight heparins Fragmin D in dogs]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10763553/),min,123,124009,DB06779,Dalteparin
,10763553,t50,"After injection of 50, 100 and 200 anti-fXaU./kg BW t50 values of 81, 123 and 182 minutes were calculated.",[Phamacokinetics of low-molecular-weight heparins Fragmin D in dogs]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10763553/),min,182,124010,DB06779,Dalteparin
,10763553,apparent volume of distribution,The apparent volume of distribution after intravenously applicated LMWH ranged between 50 and 70 ml/kg BW.,[Phamacokinetics of low-molecular-weight heparins Fragmin D in dogs]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10763553/),[ml] / [kg],50 and 70,124011,DB06779,Dalteparin
,10763553,absolute bioavailability,"The absolute bioavailability calculated for the subcutaneous NMH-injection of 50 and 100 anti-fXaU./kg BW was 107% and 104%, respectively.",[Phamacokinetics of low-molecular-weight heparins Fragmin D in dogs]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10763553/),%,107,124012,DB06779,Dalteparin
,10763553,absolute bioavailability,"The absolute bioavailability calculated for the subcutaneous NMH-injection of 50 and 100 anti-fXaU./kg BW was 107% and 104%, respectively.",[Phamacokinetics of low-molecular-weight heparins Fragmin D in dogs]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10763553/),%,104,124013,DB06779,Dalteparin
,15821819,half-life,The half-life of intravenous dalteparin is 77 minutes with slight dose-related variation.,High-dose intravenous dalteparin can be monitored effectively using standard coagulation times. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15821819/),min,77,128078,DB06779,Dalteparin
,10954342,V,The mean value of V (8.41) in the normal-weight patients was similar to that reported in the literature.,The effect of body weight on dalteparin pharmacokinetics. A preliminary study. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10954342/),,8.41,146240,DB06779,Dalteparin
,17516699,Bioavailability,Bioavailability of melagatran was 21% after the first oral dose of ximelagatran and was virtually unchanged throughout the study.,"Pharmacokinetics, preliminary efficacy and safety of subcutaneous melagatran and oral ximelagatran : a multicentre study of thromboprophylaxis in elective abdominal surgery. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17516699/),%,21,194292,DB06779,Dalteparin
,12407644,antifactor Xa activities,"Mean antifactor Xa activities 4 hours postinjection were 0.2 +/- 0.035 (SEM), 0.38 +/- 0.028, and 0.54 +/- 0.051 U/mL week 1 and 0.26 +/- 0.038, 0.40 +/- 0.055, and 0.64 +/- 0.050 U/mL week 4 for dalteparin, enoxaparin, and danaparoid, respectively.","Pharmacokinetic studies of dalteparin (Fragmin), enoxaparin (Clexane), and danaparoid sodium (Orgaran) in stable chronic hemodialysis patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12407644/),[u] / [ml],0.2,205686,DB06779,Dalteparin
,12407644,antifactor Xa activities,"Mean antifactor Xa activities 4 hours postinjection were 0.2 +/- 0.035 (SEM), 0.38 +/- 0.028, and 0.54 +/- 0.051 U/mL week 1 and 0.26 +/- 0.038, 0.40 +/- 0.055, and 0.64 +/- 0.050 U/mL week 4 for dalteparin, enoxaparin, and danaparoid, respectively.","Pharmacokinetic studies of dalteparin (Fragmin), enoxaparin (Clexane), and danaparoid sodium (Orgaran) in stable chronic hemodialysis patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12407644/),[u] / [ml],0.38,205687,DB06779,Dalteparin
,12407644,antifactor Xa activities,"Mean antifactor Xa activities 4 hours postinjection were 0.2 +/- 0.035 (SEM), 0.38 +/- 0.028, and 0.54 +/- 0.051 U/mL week 1 and 0.26 +/- 0.038, 0.40 +/- 0.055, and 0.64 +/- 0.050 U/mL week 4 for dalteparin, enoxaparin, and danaparoid, respectively.","Pharmacokinetic studies of dalteparin (Fragmin), enoxaparin (Clexane), and danaparoid sodium (Orgaran) in stable chronic hemodialysis patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12407644/),[u] / [ml],0.54,205688,DB06779,Dalteparin
,12407644,antifactor Xa activities,"Mean antifactor Xa activities 4 hours postinjection were 0.2 +/- 0.035 (SEM), 0.38 +/- 0.028, and 0.54 +/- 0.051 U/mL week 1 and 0.26 +/- 0.038, 0.40 +/- 0.055, and 0.64 +/- 0.050 U/mL week 4 for dalteparin, enoxaparin, and danaparoid, respectively.","Pharmacokinetic studies of dalteparin (Fragmin), enoxaparin (Clexane), and danaparoid sodium (Orgaran) in stable chronic hemodialysis patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12407644/),[u] / [ml],0.26,205689,DB06779,Dalteparin
,12407644,antifactor Xa activities,"Mean antifactor Xa activities 4 hours postinjection were 0.2 +/- 0.035 (SEM), 0.38 +/- 0.028, and 0.54 +/- 0.051 U/mL week 1 and 0.26 +/- 0.038, 0.40 +/- 0.055, and 0.64 +/- 0.050 U/mL week 4 for dalteparin, enoxaparin, and danaparoid, respectively.","Pharmacokinetic studies of dalteparin (Fragmin), enoxaparin (Clexane), and danaparoid sodium (Orgaran) in stable chronic hemodialysis patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12407644/),[u] / [ml],0.40,205690,DB06779,Dalteparin
,12407644,antifactor Xa activities,"Mean antifactor Xa activities 4 hours postinjection were 0.2 +/- 0.035 (SEM), 0.38 +/- 0.028, and 0.54 +/- 0.051 U/mL week 1 and 0.26 +/- 0.038, 0.40 +/- 0.055, and 0.64 +/- 0.050 U/mL week 4 for dalteparin, enoxaparin, and danaparoid, respectively.","Pharmacokinetic studies of dalteparin (Fragmin), enoxaparin (Clexane), and danaparoid sodium (Orgaran) in stable chronic hemodialysis patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12407644/),[u] / [ml],0.64,205691,DB06779,Dalteparin
,19624460,adjusted,"After the first dose, adjusted anti-Xa levels were 3.5 (2.6-5.0), 4.8 (3.3-5.5), 4.5 (3.7-7.5) x 10(-3) for the groups A, B, C; P = 0.26.",Study of bioaccumulation of dalteparin at a therapeutic dose in patients with renal insufficiency. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19624460/),1/[(10)^3],3.5,205891,DB06779,Dalteparin
,19624460,anti-Xa,"After the first dose, adjusted anti-Xa levels were 3.5 (2.6-5.0), 4.8 (3.3-5.5), 4.5 (3.7-7.5) x 10(-3) for the groups A, B, C; P = 0.26.",Study of bioaccumulation of dalteparin at a therapeutic dose in patients with renal insufficiency. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19624460/),1/[(10)^3],3.5,205892,DB06779,Dalteparin
,19624460,anti-Xa,"After the first dose, adjusted anti-Xa levels were 3.5 (2.6-5.0), 4.8 (3.3-5.5), 4.5 (3.7-7.5) x 10(-3) for the groups A, B, C; P = 0.26.",Study of bioaccumulation of dalteparin at a therapeutic dose in patients with renal insufficiency. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19624460/),1/[(10)^3],4.8,205893,DB06779,Dalteparin
,19624460,anti-Xa,"After the first dose, adjusted anti-Xa levels were 3.5 (2.6-5.0), 4.8 (3.3-5.5), 4.5 (3.7-7.5) x 10(-3) for the groups A, B, C; P = 0.26.",Study of bioaccumulation of dalteparin at a therapeutic dose in patients with renal insufficiency. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19624460/),1/[(10)^3],4.5,205894,DB06779,Dalteparin
,17063975,Cl(crea),"The pharmacokinetics of the low-molecular weight heparin (LMWH), dalteparin, was evaluated after a single intravenous bolus injection of 50 IU anti-Xa/kg in 8 healthy volunteers, 8 patients with moderate/severe renal failure (Cl(crea) 13.1-56.5 ml/min) and 8 hemodialysis patients.",Evaluation of the pharmacokinetics of dalteparin in patients with renal insufficiency. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17063975/),m,13.1-56.5,215258,DB06779,Dalteparin
,17552440,anti-Xa activity,"Mean anti-Xa activity 4 hours after enoxaparin (0.48 U/mL) approached the human therapeutic target (0.5-1.0 U/mL); however, mean trough anti-Xa activity was below detection limits.",Anticoagulant effects of low-molecular-weight heparins in healthy cats. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17552440/),[u] / [ml],0.48,231882,DB06779,Dalteparin
,17552440,anti-Xa activity,"Mean anti-Xa activity 4 hours after enoxaparin (0.48 U/mL) approached the human therapeutic target (0.5-1.0 U/mL); however, mean trough anti-Xa activity was below detection limits.",Anticoagulant effects of low-molecular-weight heparins in healthy cats. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17552440/),[u] / [ml],0.5-1.0,231883,DB06779,Dalteparin
,16616629,Maximum anti-Xa activity,"Maximum anti-Xa activity (ie, 0.42 +/- 0.13 IU/mL) was achieved 4 hours after administration (in 8 of 10 patients).",Monitoring of subcutaneous dalteparin in patients with renal insufficiency under intensive care: an observational study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16616629/),[iu] / [ml],0.42,247951,DB06779,Dalteparin
higher,18779469,trough anti-Xa level,"Bioaccumulation was defined by a trough anti-Xa level higher than 0.40 IU/mL, measured twice weekly.",Prophylaxis against deep vein thrombosis in critically ill patients with severe renal insufficiency with the low-molecular-weight heparin dalteparin: an assessment of safety and pharmacodynamics: the DIRECT study. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18779469/),[iu] / [ml],0.40,262311,DB06779,Dalteparin
<,18779469,trough anti-Xa level,"In 120 patients who had at least 1 trough anti-Xa level (427 total measurements), no patient had bioaccumulation (0%; 95% confidence interval [CI]: 0%-3.0%); the median (IQR) trough anti-Xa level was undetectable (<0.10 IU/mL [<0.10 to <0.10 IU/mL]).",Prophylaxis against deep vein thrombosis in critically ill patients with severe renal insufficiency with the low-molecular-weight heparin dalteparin: an assessment of safety and pharmacodynamics: the DIRECT study. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18779469/),[iu] / [ml],0.10,262312,DB06779,Dalteparin
,18779469,peak anti-Xa,"Based on serial measurements, peak anti-Xa levels were 0.29 to 0.34 IU/mL and trough levels were lower than 0.06 IU/mL.",Prophylaxis against deep vein thrombosis in critically ill patients with severe renal insufficiency with the low-molecular-weight heparin dalteparin: an assessment of safety and pharmacodynamics: the DIRECT study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18779469/),[iu] / [ml],0.29 to 0.34,262313,DB06779,Dalteparin
lower,18779469,trough levels,"Based on serial measurements, peak anti-Xa levels were 0.29 to 0.34 IU/mL and trough levels were lower than 0.06 IU/mL.",Prophylaxis against deep vein thrombosis in critically ill patients with severe renal insufficiency with the low-molecular-weight heparin dalteparin: an assessment of safety and pharmacodynamics: the DIRECT study. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18779469/),[iu] / [ml],0.06,262314,DB06779,Dalteparin
,18779469,trough anti-Xa,"Deep vein thrombosis occurred in 7 of 138 patients (5.1%; 95% CI, 2.5%-10.1%); major bleeding occurred in 10 patients (7.2%; 95% CI, 4.0%-12.8%), all with trough anti-Xa levels of 0.18 IU/mL or lower.",Prophylaxis against deep vein thrombosis in critically ill patients with severe renal insufficiency with the low-molecular-weight heparin dalteparin: an assessment of safety and pharmacodynamics: the DIRECT study. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18779469/),[iu] / [ml],0.18,262315,DB06779,Dalteparin
,21978598,maximum plasma heparin activities (C(max)),"Following IV injection, maximum plasma heparin activities (C(max)) were 0.67 ± 0.14, 1.44 ± 0.22 and 2.87 ± 0.38 IU anti-FXa/mL, respectively.",Pharmacokinetics of the low molecular weight heparin dalteparin in cats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21978598/),iu,0.67,265116,DB06779,Dalteparin
,21978598,maximum plasma heparin activities (C(max)),"Following IV injection, maximum plasma heparin activities (C(max)) were 0.67 ± 0.14, 1.44 ± 0.22 and 2.87 ± 0.38 IU anti-FXa/mL, respectively.",Pharmacokinetics of the low molecular weight heparin dalteparin in cats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21978598/),iu,1.44,265117,DB06779,Dalteparin
,21978598,maximum plasma heparin activities (C(max)),"Following IV injection, maximum plasma heparin activities (C(max)) were 0.67 ± 0.14, 1.44 ± 0.22 and 2.87 ± 0.38 IU anti-FXa/mL, respectively.",Pharmacokinetics of the low molecular weight heparin dalteparin in cats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21978598/),iu,2.87,265118,DB06779,Dalteparin
,21978598,half-life (t(½)),The calculated mean half-life (t(½)) was between 39 and 57 min and was not significantly dose-dependent (P=0.139).,Pharmacokinetics of the low molecular weight heparin dalteparin in cats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21978598/),min,39 and 57,265119,DB06779,Dalteparin
,21978598,volume of distribution,The volume of distribution (35-39 mL/kg) was almost equivalent to the plasma volume.,Pharmacokinetics of the low molecular weight heparin dalteparin in cats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21978598/),[ml] / [kg],35-39,265120,DB06779,Dalteparin
,21978598,C(max),"After SC injection, C(max) values of 0.41 ± 0.10, 0.86 ± 0.17 or 1.91 ± 0.16 IU anti-FXa/mL, respectively, were calculated at 91-110 min post-injection.",Pharmacokinetics of the low molecular weight heparin dalteparin in cats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21978598/),[a·anti-f·iu] / [ml],0.41,265121,DB06779,Dalteparin
,21978598,C(max),"After SC injection, C(max) values of 0.41 ± 0.10, 0.86 ± 0.17 or 1.91 ± 0.16 IU anti-FXa/mL, respectively, were calculated at 91-110 min post-injection.",Pharmacokinetics of the low molecular weight heparin dalteparin in cats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21978598/),[a·anti-f·iu] / [ml],0.86,265122,DB06779,Dalteparin
,21978598,C(max),"After SC injection, C(max) values of 0.41 ± 0.10, 0.86 ± 0.17 or 1.91 ± 0.16 IU anti-FXa/mL, respectively, were calculated at 91-110 min post-injection.",Pharmacokinetics of the low molecular weight heparin dalteparin in cats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21978598/),[a·anti-f·iu] / [ml],1.91,265123,DB06779,Dalteparin
,21978598,t(½),The t(½) values were between 106 and 122 min and were not significantly influenced by dose (P=0.784).,Pharmacokinetics of the low molecular weight heparin dalteparin in cats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21978598/),min,106 and 122,265124,DB06779,Dalteparin
,21978598,bioavailability,The bioavailability after SC injection was approximately 100%.,Pharmacokinetics of the low molecular weight heparin dalteparin in cats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21978598/),%,100,265125,DB06779,Dalteparin
,23587152,apparent elimination half-life,"After s.c. injection, the apparent elimination half-life of the dalteparin was about 4 hours, longer than that reported after intravenous (i.v.) injection, indicating a ""flip-flop"" phenomenon.",Low-molecular-weight heparin pharmacokinetics: a dual absorption model approach. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23587152/),h,4,267272,DB06779,Dalteparin
,11011804,MW,"The mean MW of these compounds ranges from 3,600 to 6,500 daltons.",Comparative pharmacokinetics of LMWHs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11011804/),daltons,"3,600 to 6,500",267803,DB06779,Dalteparin
,11011804,retention time,"The mean retention time of aXa activity varies from 5.2 (dalteparin) to approximately 7 h (enoxaparin, nadroparin).",Comparative pharmacokinetics of LMWHs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11011804/),h,5.2,267804,DB06779,Dalteparin
,11011804,retention time,"The mean retention time of aXa activity varies from 5.2 (dalteparin) to approximately 7 h (enoxaparin, nadroparin).",Comparative pharmacokinetics of LMWHs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11011804/),h,7,267805,DB06779,Dalteparin
,11011804,Bioavailability,"Bioavailability of prophylactic doses of LMWHs ranges from 86% (dalteparin) to 98% (enoxaparin, nadroparin).",Comparative pharmacokinetics of LMWHs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11011804/),%,86,267806,DB06779,Dalteparin
,11011804,Bioavailability,"Bioavailability of prophylactic doses of LMWHs ranges from 86% (dalteparin) to 98% (enoxaparin, nadroparin).",Comparative pharmacokinetics of LMWHs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11011804/),%,98,267807,DB06779,Dalteparin
,11011804,Clplasma,"The Clplasma is different for each LMWH: 16 mL/min enoxaparin, 21 mL/min nadroparin, 33 mL/min dalteparin, 19 mL/min reviparin, and 22 mL/min tinzaparin.",Comparative pharmacokinetics of LMWHs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11011804/),[ml] / [min],16,267808,DB06779,Dalteparin
,11011804,Clplasma,"The Clplasma is different for each LMWH: 16 mL/min enoxaparin, 21 mL/min nadroparin, 33 mL/min dalteparin, 19 mL/min reviparin, and 22 mL/min tinzaparin.",Comparative pharmacokinetics of LMWHs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11011804/),[ml] / [min],21,267809,DB06779,Dalteparin
,11011804,Clplasma,"The Clplasma is different for each LMWH: 16 mL/min enoxaparin, 21 mL/min nadroparin, 33 mL/min dalteparin, 19 mL/min reviparin, and 22 mL/min tinzaparin.",Comparative pharmacokinetics of LMWHs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11011804/),[ml] / [min],33,267810,DB06779,Dalteparin
,11011804,Clplasma,"The Clplasma is different for each LMWH: 16 mL/min enoxaparin, 21 mL/min nadroparin, 33 mL/min dalteparin, 19 mL/min reviparin, and 22 mL/min tinzaparin.",Comparative pharmacokinetics of LMWHs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11011804/),[ml] / [min],19,267811,DB06779,Dalteparin
,11011804,Clplasma,"The Clplasma is different for each LMWH: 16 mL/min enoxaparin, 21 mL/min nadroparin, 33 mL/min dalteparin, 19 mL/min reviparin, and 22 mL/min tinzaparin.",Comparative pharmacokinetics of LMWHs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11011804/),[ml] / [min],22,267812,DB06779,Dalteparin
